Karen Keeshan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1084476/publications.pdf

Version: 2024-02-01

64 papers	2,414 citations	218677 26 h-index	206112 48 g-index
66 all docs	66 docs citations	66 times ranked	2933 citing authors

#	Article	IF	Citations
1	Tribbles homolog 2 inactivates C/EBPÎ± and causes acute myelogenous leukemia. Cancer Cell, 2006, 10, 401-411.	16.8	232
2	Tribbles in the 21st Century: The Evolving Roles of Tribbles Pseudokinases in Biology and Disease. Trends in Cell Biology, 2017, 27, 284-298.	7.9	192
3	The requirement for Notch signaling at the Î²-selection checkpoint in vivo is absolute and independent of the preâ€“T cell receptor. Journal of Experimental Medicine, 2006, 203, 2239-2245.	8.5	184
4	Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood, 2007, 110, 3706-3714.	1.4	180
5	Differential ability of Tribbles family members to promote degradation of C/EBPÎ± and induce acute myelogenous leukemia. Blood, 2010, 116, 1321-1328.	1.4	148
6	The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1018-1023.	7.1	142
7	Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood, 2010, 116, 4948-4957.	1.4	103
8	Transcription activation function of C/EBPÎ± is required for induction of granulocytic differentiation. Blood, 2003, 102, 1267-1275.	1.4	87
9	Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia, 2001, 15, 1823-1833.	7.2	68
10	Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. Science Signaling, 2018, 11, .	3.6	66
11	Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis. Oncologist, 2000, 5, 405-415.	3.7	62
12	Negative regulation of TLX by IL-1Î² correlates with an inhibition of adult hippocampal neural precursor cell proliferation. Brain, Behavior, and Immunity, 2013, 33, 7-13.	4.1	61
13	Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. International Journal of Cancer, 2019, 145, 2201-2208.	5.1	58
14	The functionally diverse roles of tribbles. Biochemical Society Transactions, 2013, 41, 1096-1100.	3.4	57
15	Tribbles in acute leukemia. Blood, 2013, 121, 4265-4270.	1.4	47
16	Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. Nature Communications, 2018, 9, 5280.	12.8	46
17	Regulation of Trib2 by an E2F1-C/EBPÎ± feedback loop in AML cell proliferation. Blood, 2014, 123, 2389-2400.	1.4	44
18	BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 2021, 12, 241.	12.8	43

#	Article	IF	Citations
19	Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia. Blood Cells, Molecules, and Diseases, 2008, 40, 119-121.	1.4	41
20	Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. British Journal of Haematology, 2003, 123, 34-44.	2.5	35
21	Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPÎ±. Blood, 2006, 108, 1353-1362.	1.4	34
22	Pseudokinases: a tribbleâ€edged sword. FEBS Journal, 2020, 287, 4170-4182.	4.7	34
23	Elevated <scp>TRIB</scp>2 with <scp>NOTCH</scp>1 activation in paediatric/adult <scp>T</scp>â€<scp>ALL</scp>. British Journal of Haematology, 2012, 158, 626-634.	2.5	31
24	Insights into cell ontogeny, age, and acute myeloid leukemia. Experimental Hematology, 2015, 43, 745-755.	0.4	28
25	Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Experimental Hematology, 2017, 54, 40-50.	0.4	28
26	High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia, 2002, 16, 1725-1734.	7.2	27
27	Inverse and correlative relationships between TRIBBLES genes indicate non-redundant functions during normal and malignant hemopoiesis. Experimental Hematology, 2018, 66, 63-78.e13.	0.4	26
28	TRIB2 regulates normal and stress-induced thymocyte proliferation. Cell Discovery, 2016, 2, 15050.	6.7	25
29	The presence of C/EBPÎ± and its degradation are both required for TRIB2-mediated leukaemia. Oncogene, 2016, 35, 5272-5281.	5.9	25
30	A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling. Cell Death and Disease, 2018, 9, 443.	6.3	24
31	Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPÂ as a common target of TRIB1 and PML/RARA. Haematologica, 2016, 101, 1228-1236.	3.5	20
32	TRIB2 and the ubiquitin proteasome system in cancer. Biochemical Society Transactions, 2015, 43, 1089-1094.	3.4	19
33	Nfix Expression Critically Modulates Early B Lymphopoiesis and Myelopoiesis. PLoS ONE, 2015, 10, e0120102.	2.5	19
34	Human TRIB2 Oscillates during the Cell Cycle and Promotes Ubiquitination and Degradation of CDC25C. International Journal of Molecular Sciences, 2016, 17, 1378.	4.1	19
35	Regulation of NF-ÎºB by PML and PML-RARÎ±. Scientific Reports, 2017, 7, 44539.	3.3	18
36	The deubiquitinase USP7 uses a distinct ubiquitin-like domain to deubiquitinate NF-Ä¸B subunits. Journal of Biological Chemistry, 2020, 295, 11754-11763.	3.4	18

#	Article	IF	Citations
37	The regulation of sequence specific NF-Î²B DNA binding and transcription by IKKÎ² phosphorylation of NF-Î²B p50 at serine 80. Nucleic Acids Research, 2019, 47, 11151-11163.	14.5	16
38	Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2. Oncotarget, 2018, 9, 14977-14992.	1.8	15
39	Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. Experimental Hematology, 2018, 63, 1-11.	0.4	12
40	Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Advances, 2022, 6, 3126-3141.	5.2	12
41	The IÎ²B-protein BCL-3 controls Toll-like receptor-induced MAPK activity by promoting TPL-2 degradation in the nucleus. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25828-25838.	7.1	10
42	Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia. Molecular Oncology, 2021, 15, 2253-2272.	4.6	10
43	The Tribble with APL: A New Road to Therapy. Cancer Cell, 2017, 31, 612-613.	16.8	8
44	CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis. International Journal of Molecular Sciences, 2020, 21, 4266.	4.1	8
45	Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. Biochemical Pharmacology, 2021, 183, 114348.	4.4	8
46	Structure vs. Function of TRIB1â€"Myeloid Neoplasms and Beyond. Cancers, 2021, 13, 3060.	3.7	7
47	Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease. International Journal of Neuroscience, 2015, 125, 70-77.	1.6	6
48	Tribbles Homolog 2 (Trib2) Inactivates C/EBPalpha and Causes Acute Myelogenous Leukemia.. Blood, 2006, 108, 776-776.	1.4	4
49	Highlights of the 2nd International Symposium on Tribbles and Diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer. Acta Pharmaceutica Sinica B, 2019, 9, 443-454.	12.0	3
50	BET Inhibitors Potentiate Activation of p53 and Killing of AML By MDM2 Inhibitors â€" a Candidate Combination Therapy. Blood, 2018, 132, 3912-3912.	1.4	2
51	Investigation of the role of TRIB2 in normal murine hematopoiesis. Experimental Hematology, 2015, 43, S77.	0.4	1
52	Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia. Blood, 2015, 126, 674-674.	1.4	1
53	E2F1 positively regulates Trib2 pseudokinase expression and proliferation in acute leukaemia. Experimental Hematology, 2013, 41, S50.	0.4	0
54	NFIX expression critically modulates early B lymphopoiesis and myelopoiesis. Experimental Hematology, 2013, 41, S68.	0.4	0

#	Article	IF	Citations
55	NFIX influences stem and progenitor lineage fate. Experimental Hematology, 2014, 42, S54.	0.4	0
56	Targeting C/EBPalpha p42 and oncogene cooperativity in acute myeloid leukaemia. Experimental Hematology, 2014, 42, S42.	0.4	0
57	An investigation of the leukaemia initiating cell in TRIB2 mediated AML. Experimental Hematology, 2015, 43, S88.	0.4	0
58	Superenhancing AML with Trib1. Blood, 2021, 137, 8-9.	1.4	0
59	Trib1 and Trib2 but Not Trib3 Degrade C/EBPaì•and Induce Acute Myelogenous Leukemia. Blood, 2008, 112, 2950-2950.	1.4	0
60	Elucidation and Therapeutic Targeting Of The Molecular Mechanism Of TRIB2-Mediated Acute Myeloid Leukaemia. Blood, 2013, 122, 3799-3799.	1.4	0
61	The Bone Marrow Niche Distinguishes Young and Old Leukemia. Blood, 2016, 128, 1548-1548.	1.4	0
62	Abstract 3426: A synthetic lethality approach to eradicate AML via synergistic activation of pro-apoptotic p53 by MDM2 and BET inhibitors. , 2020, , .		0
63	A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors. Blood, 2020, 136, 14-14.	1.4	0
64	Detecting endogenous TRIB2 protein expression by flow cytometry and Western blotting. Methods in Enzymology, 2022, 667, 59-77.	1.0	0